Hereditary kidney cancer: Unique opportunity for disease-based therapy

Cancer

Volumn 115, Issue SUPPL. 10, 2009, Pages 2252-2261

  Linehan, W Marston ^a   Pinto, Peter A ^a   Bratslavsky, Gennady ^a   Pfaffenroth, Elizabeth ^a   Merino, Maria ^a   Vocke, Cathy D ^a   Toro, Jorge R ^a   Bottaro, Donald ^a   Neckers, Len ^a   Schmidt, Laura S ^a,b   Srinivasan, Ramaprasad ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Birt Hogg Dube; Fumarate hydratase; Kidney; MET; Neoplasm; Von Hippel Lindau

Indexed keywords

ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; ESTRONE; FUMARATE HYDRATASE; GSK 1363089; HYPOXIA INDUCIBLE FACTOR; INTERFERON; RAPAMYCIN; SCATTER FACTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; XL 880;

ANGIOMYOLIPOMA; AUTOSOMAL DOMINANT DISORDER; BIRT HOGG DUBE SYNDROME; CANCER PATIENT; CANCER RISK; CHROMOPHOBE ADENOMA; CITRIC ACID CYCLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFERENCE PAPER; FAMILIAL CANCER; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; HEREDITARY LEIOMYOMATOSIS RENAL CELL CARCINOMA; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LEIOMYOMATOSIS; MUTATION; NONHUMAN; ONCOGENE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; TUBEROUS SCLEROSIS; TUMOR GENE; UTERUS MYOMA;

CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS; NEOPLASTIC SYNDROMES, HEREDITARY;

EID: 65949089138     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24230     Document Type: Conference Paper

References (66)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Linehan WM, Yang JC, Rini B. Cancer of the kidney. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:1331-1358.
3. Linehan WM, Vasselli J, Srinivasan R, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res. 2004;10:6282S-6289S.
4. Linehan WM, Zbar B. Focus on kidney cancer. Cancer Cell. 2004;6:223-228.
5. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170:2163-2172.
6. Walther MM, Lubensky IA, Venzon D, Zbar B, Linehan WM. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol. 1995;154:2010-2014.
7. Blansfield JA, Choyke L, Morita SY, et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine tumors (PNETs). Surgery. 2007;142:814-818.
8. Walther MM, Reiter R, Keiser HR, et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol. 1999;162:659-664.
9. Wong WT, Agron E, Coleman HR, et al. Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis. Arch Ophthalmol. 2007;125:239-245. (Pubitemid 46256528)
10. Lonser RR, Glenn GM, Walther MM, et al. von Hippel- Lindau disease. Lancet. 2003;361:2059-2067.
11. Choo D, Shotland L, Mastroianni M, et al. Endolymphatic sac tumors in von Hippel-Lindau disease. J Neurosurg. 2004;100:480-487. (Pubitemid 38269076)
12. Walther MM, Choyke PL, Weiss G, et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol. 1995;153:913-916.
13. Herring JC, Enquist EG, Chernoff A, Linehan WM, Choyke PL, Walther MM. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol. 2001;165:777-781. (Pubitemid 32156275)
14. Drachenberg DE, Mena OJ, Choyke PL, Linehan WM, Walther MM. Parenchymal sparing surgery for central renal tumors in patients with hereditary renal cancers. J Urol. 2004;172:49-53.
15. Grubb RL III, Choyke PL, Pinto PA, Linehan WM, Walther MM. Management of von Hippel-Lindau-associated kidney cancer. Nat Clin Pract Urol. 2005;2:248-255.
16. Bratslavsky G, Liu JJ, Johnson AD, et al. Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. J Urol. 2007;179:67-70.
17. Rogers CG, Singh A, Blatt AM, Linehan WM, Pinto PA. Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur Urol. 2008;53:514-523.
18. Duffey BG, Choyke PL, Glenn GM, et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol. 2004;172:63-65. (Pubitemid 41615039)
19. Latif F, Tory K, Gnarra JR, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317-1320. (Pubitemid 23231974)
20. Stolle C, Glenn GM, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat. 1998;12:417-423. (Pubitemid 28512618)
21. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7:85-90. (Pubitemid 24232386)
22. Nickerson ML, Jaeger E, Durocher JA, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008;14:4726-4734.
23. Cohen AJ, Li FP, Berg S, et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med. 1979;301:592-595. (Pubitemid 10226456)
24. Eleveld MJ, Bodmer D, Merkx G, et al. Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15). Genes Chromosomes Cancer. 2001;31:23-32. (Pubitemid 32274129)
25. Podolski J, Byrski T, Zajaczek S, et al. Characterization of a familial RCC-associated t(2;3)(q33;q21) chromosome translocation. J Hum Genet. 2001;46:685-693. (Pubitemid 34037328)
26. Schmidt L, Li F, Brown RS, et al. Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. Cancer J Sci Am. 1995;1:191-195.
27. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-2524. (Pubitemid 43854967)
28. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. (Pubitemid 46089672)
29. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134. (Pubitemid 46089673)
30. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.
31. Zbar B, Tory K, Merino MJ, et al. Hereditary papillary renal cell carcinoma. J Urol. 1994;151:561-566. (Pubitemid 24054684)
32. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68-73. (Pubitemid 27198158)
33. Schmidt L, Junker K, Weirich G, et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res. 1998;58:1719-1722. (Pubitemid 28215099)
34. Lubensky IA, Schmidt L, Zhuang Z, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol. 1999;155:517-526. (Pubitemid 29370401)
35. Ornstein DK, Lubensky IA, Venzon D, Zbar B, Linehan WM, Walther MM. Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer. J Urol. 2000;163:431-433.
36. Schmidt LS, Nickerson ML, Angeloni D, et al. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the Met proto-oncogene. J Urol. 2004;172:1256-1261.
37. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18:2343-2350. (Pubitemid 29192711)
38. Choyke PL, Walther MM, Glenn GM, et al. Imaging features of hereditary papillary renal cancers. J Comput Assist Tomogr. 1997;21:737-741. (Pubitemid 28049618)
39. Chernoff A, Choyke PL, Linehan WM, Walther MM. Parenchymal sparing surgery in a patient with multiple bilateral papillary renal cancer. J Urol. 2001;165:1623-1624.
40. Srinivasan R, Choueiri TK, Vaishampayan U, et al. A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC) [abstract]. J Clin Oncol. 2008;26(suppl):5103.
41. Birt AR, Hogg GR, Dube WJ. Hereditary multiple fibro-folliculomas with trichodiscomas and acrochordons. Arch Dermatol. 1977;113:1674-1677.
42. Zbar B, Alvord WG, Glenn GM, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev. 2002;11:393-400. (Pubitemid 34408219)
43. Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol. 2002;26:1542-1552. (Pubitemid 35387218)
44. Pavlovich CP, Grubb RL, Hurley K, et al. Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol. 2005;173:1482-1486. (Pubitemid 40524753)
45. Schmidt LS, Warren MB, Nickerson ML, et al. Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet. 2001;69:876-882.
46. Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell. 2002;2:157-164.
47. Schmidt LS, Nickerson ML, Warren MB, et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet. 2005;76:1023-1033. (Pubitemid 40705436)
48. Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci USA. 2006;103:15552-15557.
49. Hasumi H, Baba M, Hong SB, et al. Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene. 2008;415:60-67.
50. Vocke CD, Yang Y, Pavlovich CP, et al. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors. J Natl Cancer Inst. 2005;97:931-935. (Pubitemid 41417945)
51. Baba M, Furihata M, Hong SB, et al. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst. 2008;100:140-154.
52. Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA. 2001;98:3387-13382 (Pubitemid 32220855)
53. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003;73:95-106. (Pubitemid 36793783)
54. Kiuru M, Launonen V. Hereditary leiomyomatosis and renal cell cancer (HLRCC). Curr Mol Med. 2004;4:869-875.
55. Grubb RL III, Franks ME, Toro J, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol. 2007;177:2074-2080.
56. Merino MJ, Torres-Cabala C, Pinto P, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol. 2007;31:1578-1585.
57. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30:406-410.
58. Wei MH, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet. 2006;43:18-27. (Pubitemid 43099991)
59. Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005;8:143-153.
60. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287:848-851.
61. Vanharanta S, Buchta M, McWhinney SR, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet. 2004;74:153-159. (Pubitemid 38085246)
62. Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst. 2008;100:1260-1262.
63. Lane BR, Aydin H, Danforth TL, et al. Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid. J Urol. 2008;180:836-843.
64. Seyam RM, Bissada NK, Kattan SA, et al. Changing trends in presentation, diagnosis and management of renal angiomyolipoma: comparison of sporadic and tuberous sclerosis complex-associated forms. Urology. 2008;72:1077-1082.
65. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358:140-151.
66. Gad S, Lefevre SH, Khoo SK, et al. Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer. 2007;96:336-340.